Importance: A clearer definition of the role of neurofilament light chain (NFL) as a biomarker in amyotrophic lateral sclerosis (ALS) is needed. Objectives: To assess the ability of NFL to serve as a diagnostic biomarker in ALS and the prognostic value of cerebrospinal fluid NFL in patients with ALS. Design, Setting, and Participants: In this single-center, retrospective, longitudinal study, disease progression was assessed by the ALS Functional Rating Score-Revised and the ALS Milano-Torino Staging system at baseline and 6, 12, 24, and 36 months. Cerebrospinal fluid samples were obtained from 176 patients admitted to the Department of Neurosciences of the University of Padua, Padova, Italy, from January 1, 2010, through February 29, 2016. Patients with ALS underwent ambulatory follow-up at the same department. Main Outcomes and Measures: Levels of NFL. Results: The study included 94 patients with ALS (64 men [36.4%] and 30 women [17.0%]; median age, 62.5 years), 20 patients with frontotemporal dementia (FTD) (8 men [4.5%] and 12 women [6.8%]; median age, 65 years), 18 patients with motor neuropathies (14 men [8.0%] and 4 women [2.3%]; median age, 63 years), and 44 controls (24 men [13.6%] and 20 women [11.4%]; median age, 54 years). Log-transformed NFL (log[NFL]) concentrations were higher in the ALS and FTD groups compared with the motor neuropathies and control groups (hazard ratio [HR], 2.45; 95% CI, 1.66-3.61; P < .001). Patients with typical ALS (HR, 1.0 [reference]), progressive bulbar palsy (HR, 1.48; 95% CI, 0.58-3.75; P = .41), and upper motor neuron dominant ALS (HR, 0.12; 95% CI, 0.02-0.61; P = .01) had higher levels of NFL than did those with flail arm or leg syndrome (HR, 0.28; 95% CI, 0.08-0.10; P = .049) and progressive muscular atrophy (HR, 0.17; 95% CI, 0.22-1.36; P = .10). There was an inverse correlation between log[NFL] concentration and overall survival (HR, 2.45; 95% CI, 1.66-3.61; P < .001). There was no evidence of different log[NFL] concentrations and survival in genetic ALS. Conclusions and Relevance: This study confirms the role of NFL as a biomarker in ALS. Elevation in NFL levels in patients with upper motor neuron involvement and FTD might reflect the corticospinal tract degeneration. Low NFL levels in patients with lower motor neuron signs might be a prognostic indicator of milder phenotypes of disease.
Importance: A clearer definition of the role of neurofilament light chain (NFL) as a biomarker in amyotrophic lateral sclerosis (ALS) is needed. Objectives: To assess the ability of NFL to serve as a diagnostic biomarker in ALS and the prognostic value of cerebrospinal fluid NFL in patients with ALS. Design, Setting, and Participants: In this single-center, retrospective, longitudinal study, disease progression was assessed by the ALS Functional Rating Score-Revised and the ALS Milano-Torino Staging system at baseline and 6, 12, 24, and 36 months. Cerebrospinal fluid samples were obtained from 176 patients admitted to the Department of Neurosciences of the University of Padua, Padova, Italy, from January 1, 2010, through February 29, 2016. Patients with ALS underwent ambulatory follow-up at the same department. Main Outcomes and Measures: Levels of NFL. Results: The study included 94 patients with ALS (64 men [36.4%] and 30 women [17.0%]; median age, 62.5 years), 20 patients with frontotemporal dementia (FTD) (8 men [4.5%] and 12 women [6.8%]; median age, 65 years), 18 patients with motor neuropathies (14 men [8.0%] and 4 women [2.3%]; median age, 63 years), and 44 controls (24 men [13.6%] and 20 women [11.4%]; median age, 54 years). Log-transformed NFL (log[NFL]) concentrations were higher in the ALS and FTD groups compared with the motor neuropathies and control groups (hazard ratio [HR], 2.45; 95% CI, 1.66-3.61; P < .001). Patients with typical ALS (HR, 1.0 [reference]), progressive bulbar palsy (HR, 1.48; 95% CI, 0.58-3.75; P = .41), and upper motor neuron dominant ALS (HR, 0.12; 95% CI, 0.02-0.61; P = .01) had higher levels of NFL than did those with flail arm or leg syndrome (HR, 0.28; 95% CI, 0.08-0.10; P = .049) and progressive muscular atrophy (HR, 0.17; 95% CI, 0.22-1.36; P = .10). There was an inverse correlation between log[NFL] concentration and overall survival (HR, 2.45; 95% CI, 1.66-3.61; P < .001). There was no evidence of different log[NFL] concentrations and survival in genetic ALS. Conclusions and Relevance: This study confirms the role of NFL as a biomarker in ALS. Elevation in NFL levels in patients with upper motor neuron involvement and FTD might reflect the corticospinal tract degeneration. Low NFL levels in patients with lower motor neuron signs might be a prognostic indicator of milder phenotypes of disease.
Authors: Johannes Brettschneider; Vivianna M Van Deerlin; John L Robinson; Linda Kwong; Edward B Lee; Yousuf O Ali; Nathaniel Safren; Mervyn J Monteiro; Jon B Toledo; Lauren Elman; Leo McCluskey; David J Irwin; Murray Grossman; Laura Molina-Porcel; Virginia M-Y Lee; John Q Trojanowski Journal: Acta Neuropathol Date: 2012-03-18 Impact factor: 17.088
Authors: P Singh; J Yan; R Hull; S Read; J O'Sullivan; R D Henderson; S Rose; J M Greer; P A McCombe Journal: J Neurol Sci Date: 2011-02-23 Impact factor: 3.181
Authors: C Cerami; A Marcone; C Crespi; S Iannaccone; C Marangoni; A Dodich; M C Giusti; M Zamboni; V Golzi; S F Cappa Journal: J Neurol Sci Date: 2015-03-01 Impact factor: 3.181
Authors: Stefan Lehnert; Julia Costa; Mamede de Carvalho; Janine Kirby; Magdalena Kuzma-Kozakiewicz; Claudia Morelli; Wim Robberecht; Pamela Shaw; Vincenzo Silani; Petra Steinacker; Hayrettin Tumani; Philip Van Damme; Albert Ludolph; Markus Otto Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2014-02-28 Impact factor: 4.092
Authors: Ching-Hua Lu; Axel Petzold; Jo Topping; Kezia Allen; Corrie Macdonald-Wallis; Jan Clarke; Neil Pearce; Jens Kuhle; Gavin Giovannoni; Pietro Fratta; Katie Sidle; Mark Fish; Richard Orrell; Robin Howard; Linda Greensmith; Andrea Malaspina Journal: J Neurol Neurosurg Psychiatry Date: 2014-07-09 Impact factor: 10.154
Authors: Mariah L Hoye; Erica D Koval; Amy J Wegener; Theodore S Hyman; Chengran Yang; David R O'Brien; Rebecca L Miller; Tracy Cole; Kathleen M Schoch; Tao Shen; Tomonori Kunikata; Jean-Philippe Richard; David H Gutmann; Nicholas J Maragakis; Holly B Kordasiewicz; Joseph D Dougherty; Timothy M Miller Journal: J Neurosci Date: 2017-04-17 Impact factor: 6.167
Authors: Adam L Boxer; Michael Gold; Howard Feldman; Bradley F Boeve; Susan L-J Dickinson; Howard Fillit; Carole Ho; Robert Paul; Rodney Pearlman; Margaret Sutherland; Ajay Verma; Stephen P Arneric; Brian M Alexander; Bradford C Dickerson; Earl Ray Dorsey; Murray Grossman; Edward D Huey; Michael C Irizarry; William J Marks; Mario Masellis; Frances McFarland; Debra Niehoff; Chiadi U Onyike; Sabrina Paganoni; Michael A Panzara; Kenneth Rockwood; Jonathan D Rohrer; Howard Rosen; Robert N Schuck; Holly D Soares; Nadine Tatton Journal: Alzheimers Dement Date: 2020-01-06 Impact factor: 21.566
Authors: Michael Benatar; Lanyu Zhang; Lily Wang; Volkan Granit; Jeffrey Statland; Richard Barohn; Andrea Swenson; John Ravits; Carlayne Jackson; Ted M Burns; Jaya Trivedi; Erik P Pioro; James Caress; Jonathan Katz; Jacob L McCauley; Rosa Rademakers; Andrea Malaspina; Lyle W Ostrow; Joanne Wuu Journal: Neurology Date: 2020-05-08 Impact factor: 9.910